Tim Disher, Senior Director, Biostatistics, Value & Evidence“We provide holistic commercialization services by working with clients throughout a product’s life cycle from early-stage strategic planning and launch, to post-launch marketing support,” says Tim Disher, senior director, biostatistics, value & evidence, EVERSANA. “Our goal is to ensure patients have timely access to effective treatments by helping out clients to bring therapies and technologies to the market.”
Most important, EVERSANA eliminates pharmaceutical companies’ need to engage with multiple vendors. They are the one-stop shop that can handle everything for clients working with a shared purpose and vision.
What enables EVERSANA to provide such comprehensive service is its team of seasoned HEOR researchers and industry experts, who are always focused on improving healthcare outcomes.
They have a holistic understanding of different markets. This enables the team to make crucial changes to a specific project based on the market of their clients’ preferences—be itthe U.S., Europe, or APAC. The ability to operate on a global scale has turned EVERSANA into a leader in this space.
For instance, one of EVERSANA’s HEOR clients developed a new drug for non-small cell lung cancer. The client was striving to evaluate multiple lines of therapy to understand how the drug could benefit payers in different ways. EVERSANA’s HEOR and Value & Evidence team developed a sophisticated micro simulation called discrete event simulation to simulate the patient profiles across Canada as they move from their diagnosis to multiple lines of therapy while predicting cost and outcomes. The model is currently being used by clients beyond Canada for different therapeutic indications.
The capable team has equipped EVERSANA with the capability to serve numerous global pharmaceutical companies. Many of the company’s clients, in fact, have been working with it for years now.
We provide holistic commercialization services by working with clients throughout a product’s life cycle from early-stage strategic planning and launch, to post-launch marketing support
EVERSANA’s indomitable fervor to drive clients through all the complexities allows it to continuously improve healthcare outcomes. The company understands that commercializing a new product in the market is no less than an uphill journey, requiring pharmaceutical companies to address the demand of different stakeholders, including regulators, patients, and payers. Given this situation, a partner like EVERSANA and specifically their best-in-class value & evidence solutions can really make a difference by supporting clients from pre-launch to post-launch.
EVERSANA CONSULTING Named a Top Ranked Consulting Firm by Vault Across Asia Pacific
Wednesday, March 15, 2023
SINGAPORE and CHICAGO - EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry, today announced its strategic consulting arm EVERSANA® CONSULTING, has been named to Vault's 2023 Top Consulting Ranking in the Asia Pacific (APAC) region.
The EVERSANA CONSULTING APAC team ranked in the Top 10 for several individual categories, including quality of life and diversity. This is the first year the team has participated in the regional rankings and follows the recent announcement that EVERSANA's North America team was also named a Top 50 Boutique Consulting firm by Vault in early February.
"Our consulting team across the Asia Pacific region continues to grow and create tremendous impact for our clients in helping solve their most complex commercialization challenges," said Jim Lang, CEO at EVERSANA. "Vault's ranking is a testament to our team's commitment to world-class work, a vibrant culture and career growth opportunities for experts in the region."
Vault's Asia-Pacific Consulting listing is based on a survey of more than 90 firms and 1,000 professionals who anonymously shared rankings on workplace topics including firm culture, compensation, work-life balance, business outlook and more.
Vault's Firsthand Findings note that EVERSANA CONSULTING is "growing quickly in the region and suggest that opportunities abound for any consultant who is willing to put in the time and take on new responsibilities and stretch roles." To view the profile, click here.
EVERSANA CONSULTING is the global consulting services arm of EVERSANA, serving a broad range of large and small biopharma, med tech and digital therapeutics companies. The team combines business strategy, launch excellence and commercial execution to provide end-to-end advisory services to clients. To learn more, visit https://www.eversana.com/global/asia-pacific/consulting/.
